Investigating Factors Influencing the Long-Term Outcome of Teriparatide Treatment on the Risk of Hip Fracture. Is sequential treatment essential?
文献摘要
Introduction Teriparatide (TPTD) is an anabolic therapy for severe osteoporosis. Clinical trials have shown its efficacy in reducing vertebral and non-vertebral fractures, data on hip fracture prevention in real-world settings and the impact of sequential antiresorptive (AR) therapy remain limited. Methods We conducted a retrospective cohort study using the Hungarian National Health Insurance Database, which covers the entire population (~9.7 million). Patients with osteoporosis who received TPTD between 2010 and 2023, with treatment initiated by January 1, 2022. Hip fractures were tracked from day 180 after TPTD initiation for up to five years. Adherence was assessed via medication possession ratio. Post-TPTD AR therapy (bisphosphonate or denosumab) and the timing of its initiation were evaluated as factors influencing hip fracture risk. Poisson regression models were applied, adjusting for demographics, prior fractures, and healthcare utilization. Results Among 8,893 eligible patients, 574 hip fractures occurred during follow-up. High adherence was associated with reduced hip fracture risk by 20% (p Conclusions The efficacy of teriparatide treatment was associated with patient adherence and the number of prior fractures. Neglecting to initiate AR treatment following teriparatide therapy, or starting it late, was strongly linked to an increased risk of hip fractures. Our findings provide real-world data supporting timely initiation of AR therapy post-TPTD for sustained fracture prevention.